Drugs / Fenebrutinib
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03596632 | Jul → Aug 2018 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT03290703 | Apr 2017 → Oct 2018 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03174041 | Apr → Jun 2017 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03188783 | Jan → Aug 2017 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02699710 | Sep 2015 → May 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01991184 | Dec 2013 → Mar 2022 | diffuse large B-cell lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT07161258 | Oct 2025 → Jun 2027 expected | multiple sclerosis | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT05119569 | Mar 2022 → Mar 2023 overdue | multiple sclerosis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03693625 | Sep 2018 → Oct 2019 | urticaria | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03407482 | Jan 2018 → Nov 2019 | systemic lupus erythematosus | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03137069 | May 2017 → Sep 2019 | chronic urticaria | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02908100 | Jan 2017 → May 2019 | systemic lupus erythematosus | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02983227 | Nov 2016 → Jul 2019 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02833350 | Sep 2016 → Jul 2018 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT04586023 | Mar 2021 → Sep 2025 overdue | multiple sclerosis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04586010 | Mar 2021 → Jan 2026 overdue | multiple sclerosis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04544449 | Oct 2020 → Sep 2025 overdue | primary progressive multiple sclerosis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fenebrutinib | “Fenebrutinib (GDC-0853) is a noncovalent, oral, and highly selective inhibitor of Bruton's tyrosine kinase (BTK).” PMID 34042314 ↗ Aug 2021 |
| Known as | G-02599853 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4065122 ↗ |
| Known as | GDC-0853 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02699710 ↗ |
| Known as | RG-7845 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4065122 ↗ |
| Known as | RO-7010939 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4065122 ↗ |
| Action | Inhibit | “inhibitor of Bruton's tyrosine kinase (BTK)” PMID 34042314 ↗ Aug 2021 |
| Modality | Small molecule | — CHEMBL4065122 ↗ |
| Route | Oral | “administered orally” NCT02699710 ↗ |
| Target | BTK | “inhibitor of Bruton's tyrosine kinase (BTK)” PMID 34042314 ↗ Aug 2021 |